<DOC>
	<DOCNO>NCT02715011</DOCNO>
	<brief_summary>The purpose study identify recommend Phase 2 dose ( ) ( RP2D ) schedule JNJ-63709178 Part 1 characterize safety tolerability JNJ-63709178 RP2D ( ) Part 2 .</brief_summary>
	<brief_title>Dose Escalation Study JNJ-63709178 , Humanized CD123 x CD3 DuoBody Subjects With Relapsed Refractory Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description>This first-in-human ( FIH ) Phase 1 , open-label ( identity assign study drug know ) , multicenter , dose escalation study dose expansion identify RP2D evaluate safety , tolerability , preliminary antitumor activity JNJ-63709178 adult subject relapse refractory acute myeloid leukemia ( AML ) ineligible exhaust standard therapeutic option . The study divide 3 period : Screening Phase ( 28 day first dose study drug ) , Treatment Phase ( first dose study drug last dose study drug ) Post-treatment Follow-up Phase ( end study participation end study ) . Subjects ' safety monitor throughout study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>A diagnosis acute myeloid leukemia ( AML ) accord World Health Organization 2008 criterion relapse refractory disease ineligible exhausted standard therapeutic option . Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 1 Hematology laboratory parameter within Protocol specify range Chemistry laboratory parameter within Protocol specify range A woman childbearing potential must negative highly sensitive serum ( beta human chorionic gonadotropin [ bhCG ] ) urine test prior first dose study drug Acute promyelocytic leukemia Active central nervous system involvement Prior solid organ transplantation Prior hematopoietic stem cell transplant within 6 month enrollment . If subject allogenic transplant must apparent sign graft versus host disease subject must immunosuppressive therapy Prior treatment CD123xCD3 bispecific agent , T cell express CD123 specific chimeric antigen receptor , toxinconjugated CD123 antibody ; prior treatment naked antiCD123 monoclonal antibody permit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Leukemia , Myeloid , Acute</keyword>
	<keyword>JNJ-63709178</keyword>
</DOC>